Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Keld Per Kjeldsen
Drug-drug interaction (DDI), defined as an interaction between two or more drugs, has been found to occur in up to 28 % of hospitalized patients. DDIs may be potentially or clinically relevant. Clinically harmful DDIs can occur with many cardiovascular drugs, e.g. lipid lowering agents (rhabdomyolysis), anticoagulants (bleeding), antiplatelets (bleeding) and antiarrhythmic agents (sudden cardiac death).The number of interactions that the cardiologist should be aware of is rapidly expanding with the development of new drugs. The cardiologist must be aware of interactions among cardiovascular drugs. Also, since many patients are in pharmacotherapy also for non-cardiovascular diseases, the cardiologist should keep in mind potential interactions among cardiovascular and non-cardiovascular drugs, as well as interactions among non-cardiovascular drugs.It was underlined that there is a need for computerized systems that check prescriptions for harmful interactions. At present, such systems are only rarely available to cardiologists working in hospitals or in private practice in Europe. The suggestion was that ESC might consider providing the information on harmful interactions needed, to partner in developing such a computer system and make it available to European cardiologists maybe on an EU-funded basis.
Drug interactions: what the cardiologist should know
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved